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Case presentation
A 59-year-old black man developed end-stage renal disease second-
ary to hypertension. Maintenance hemodialysis was initiated 9 years
ago, and 3 years ago he received a cadaveric renal transplant. He
experienced three rejection episodes over the following 6 months, but
renal function stabilized at an adequate level.
Two years ago, however, gradually worsening renal function was
noted. Renal biopsy at that time showed moderately severe chronic
rejection, and hemodialysis was reinstituted one month later. Because
of moderate residual urine output (500—600 cc/day), he was dialyzed
only 2 times weekly, 4 hours each time, at a blood flow of 200 mI/mm
and dialysate flow of 500 mI/mm. Initially, the blood urea nitrogen
(BUN) and serum creatinine were in the range of 62—75 mg/dl and 13—15
mg/dl, respectively; the hematocrit was stable at 25%. Over the next
few months, the predialysis BUN (measured on a monthly basis)
gradually rose to 90—100 mg/dl; the total CO2 decreased to 14 mM/liter,
The hematocrit was approximately 20% and he required approximately
two units of packed red blood cells per month to maintain this level.
Kinetic modeling was performed 9 months ago. The KT/V was 0.78 (K
= dialyzer clearance at the specified blood flow, T time on dialysis,
V = volume of distribution of urea). The residual glomerular filtration
rate was less than 2 mI/mm, and the 'time-averaged concentration" of
BUN (TACUI.) was 73 mg/dl. The protein catabolic rate was calculated
to be 0.77 g/kg/day.
Eight months ago, he complained of shortness of breath on exertion
and developed paroxysmal nocturnal dyspnea; examination disclosed
bilateral rales. His estimated "dry weight" was reduced by 2 kg during
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hemodialysis and he felt less dyspneic. Seven months ago, however, he
complained of a cough productive of sputum, and he had chills and a
temperature of 101.8° F.
When first seen at Vanderbilt University Medical Center (VUMC), he
had an infiltrate in the right midlung field consistent with pneumonia. A
sputum culture subsequently grew H. influenza, which was sensitive to
amoxicillin/clavulonate. A plain chest film revealed bilateral pleural
effusions and signs consistent with congestive heart failure. An
echocardiogram demonstrated moderate anterior and posterior pericar-
dial fluid without evidence of tamponade. Neurologic examination
showed a fluctuating mental status, with good orientation to person and
place but not to time and date. Occasionally, he was confused and was
unable to follow a train of thought or to follow commands. His speech
was not dysarthric. He had spontaneous myoclonus of his arms and legs
at rest. Cranial nerves were intact, and motor strength and reflexes
were within normal limits. He had decreased vibratory, light-touch,
pinprick, and proprioceptor responses distally in both legs. At the time
of admission to VUMC, the BUN was 112 mg/dl; serum creatinine, 19
mg/dl; and total CO2. 12 mM/liter. The albumin was 2.9 g/dl. Hemato-
crit was 17%. The administration of intravenous antibiotics was fol-
lowed by a rapid defervescence. He was dialyzed daily; postdialysis
estimated dry weight, which fell to 63 kg, was approximately 7 kg below
his previously estimated dry weight, and approximately 28 kg less than
his "ideal body weight." The signs and symptoms of fluid overload
gradually improved. His mental status and myoclonus also improved
gradually, and he was discharged on a regimen of thrice-weekly
dialysis, at a blood flow of 350 mI/mm and a dialysate flow of 500
mI/mm.
Two months following discharge, he felt much better and his appetite
had improved. The protein catabolic rate was 1.26 glkg/day, and the
TACU was 47 mg/dl; the KT/V was calculated to be 1.38. His
estimated dry weight increased gradually to 73 kg without any evidence
of fluid overload. The hematocrit has stabilized at 25% without trans-
fusion, and the pain and numbness in his legs have improved signifi-
cantly.
Five months ago, he was seen in Day Surgery for carpal-tunnel
release after he complained of numbness and tingling in the median
nerve distribution of both hands, with the symptoms more acute in his
left (access) arm than in his right. A radiograph of the hands showed a
radiolucent lesion in the head of the left radius. Subsequent pathologic
examination of the carpal-tunnel sheath demonstrated staining with
Congo red, sensitive to permanganate pretreatment; the tissue also
stained positively with fluorescein-conjugated anti-p2 microglobulin.
Discussion
D. RAYMOND M. HAKIM (Director, Clinical Services, Divi-
sion of Nephrology, and Associate Professor of Medicine,
Vanderbilt Hospital, Nashville, Tennessee): Nephrologists who
care for patients undergoing chronic dialysis are often asked by
patients to reduce their dialysis time or frequency. The recent
availability of "high-flux" and "high-efficiency" dialyzers has
made it possible to reduce the time of dialysis to considerably
less than that only a decade ago. Economic issues also have
contributed to the trend toward shorter dialysis. Unless enough
attention is paid to criteria that determine the adequacy of
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dialysis, however, I believe that an inappropriate reduction in
dialysis time might not only increase morbidity but also the
mortality rate in these patients.
This trend toward shorter dialysis time has come about at a
time when technological innovations in the manufacturing of
dialysis membranes have led to improvements in their biocom-
patibiity and to a better understanding of the role that blood-
membrane interactions play in the pathogenesis of the compli-
cations of dialysis therapy. Selection of the appropriate
membrane thus has become an increasingly important compo-
nent of the dialysis prescription. Although biocompatibility of
these membranes does affect acute intradialytic events, the
characteristics of the dialysis membrane also have an important
impact on interdialytic patient morbidity.
The patient presented today highlights specific clinical pre-
sentations of these two important issues, that is, dialysis
duration and membrane characteristics. Although on the sur-
face these issues are not directly related, I believe that they
should be considered together because they relate to the most
critical dialysis issue—the adequacy of dialysis. Too short a
dialysis leads to inadequate removal of small molecules (urea),
whereas use of a relatively impermeable membrane can lead to
inadequate removal of "middle-molecules" (for example, f32-
microglobulin). In my discussion today, I will examine each
issue separately, but it is obvious that both issues can surface in
the same patient, as described in this case.
Urea removal
Studies to determine optimal prescriptions for dialysis usu-
ally have compared "standard treatment" with reduced "dial-
ysis dose." Thus, although these studies have allowed us to
recognize inadequate dialysis clinically, no studies have defined
the "optimal" dialysis prescription. For the purposes of this
discussion, I would like to define optimal dialysis prescription
as one that does not increase, but may reduce, the morbidity
and mortality associated with renal failure and dialysis. Never-
theless, measures for avoiding inadequate dialysis are a first
step in the process of optimizing therapy.
The National Cooperative Dialysis Study (NCDS) provided
the most comprehensive look at the adequacy of dialysis.
Sponsored by the National Institutes of Health, it prospectively
examined the clinical outcomes of four different dialysis regi-
mens [1, 2]. These investigations were based on elegant mod-
eling of the dialysis procedure by Gotch [3, 4], Sargent [5], and
others [6, 7]. The choice of urea as the principal "uremic toxin"
in these models was based on historic considerations [8] and the
fact that urea is produced stoichiometrically from net protein
catabolism [9]. Urea is also an easily measurable substance of
low molecular weight and rapid diffusivity, to which a single-
pool kinetic model could be applied. In an attempt to define
separately the potential impact of "middle molecules," which
were difficult to measure and likely to be governed by diffusion
across multiple compartments, dialysis time was used as the
surrogate for middle molecules [1]. The underlying, and reason-
able, assumption was that longer dialysis time would allow a
gradual reduction of the level of these molecules.
In the NCDS study, 165 patients were randomized into 4
groups and each was treated with different dialysis regimens.
Table 1 shows these groups and their control parameters. The
independent variables used in the study were two primary
Table 1. Designated groups of the NCDS study
Experimental group
Dialysis
time
(hours)
BUN, mg/dl
Predialysis
(midweek)
Time-
averaged
I (long dialysis time, low BUN)
II (long dialysis time, high BUN)
Ill (short dialysis time, low BUN)
IV (short dialysis time, high BUN)
4.5 to 5.0
4.5 to 5.0
2.5 to 3.5
2.5 to 3.5
60 to 80
110 to 130
60 to 80
110 to 130
50
100
50
100
treatment parameters, namely, the length of dialysis treatment
and TACurea, defined in a simplified mathematical formulation
as:
TACurea = (1)
where C is the concentration of BUN at the initiation of
dialysis, C2 is the concentration of BUN at the end of dialysis,
C3 is the concentration of BUN at the beginning of the next
dialysis, Td is the dialysis time, and 'd is the interdialysis time.
The results of the study showed a significant difference in
clinical outcome, defined by withdrawal from the study either
for medical reasons or for hospitalizations other than those
related to vascular access [10]. Withdrawal from the experimen-
tal phase for medical reasons was significantly greater in the
high TACurea groups than in the lower TACurea groups; hospi-
talizations (non-access-related) also were significantly higher in
the high TACurea groups. At the end of one year, the proportion
of patients remaining out of the hospital was 86% for group I,
46% for group II, 69% for group III, and 31% for group IV.
Dialysis time was not a statistically independent risk factor in
clinical outcomes in the initial report [1]. Subsequent analysis,
however, indicated that in the 2 groups with high TACua
(groups II and IV; Table 1), more patients with the shorter
dialysis time were hospitalized, even when TACurea was similar
[10, 11].
In the context of this discussion of the adequacy of dialysis,
it is important that we review some of the reasons for with-
drawal from the study and for hospitalization in the high-
TACurea group. What were the specific long-term complications
of inadequate dialysis? Of the patients in group IV (high
TACurea, short time), 44% had at least one morbid cardiovas-
cular event, compared with 11% of patients in the control group
(I). Similarly, 17 of 23 hospitalizations and 5 of 14 dropouts in
the high-TAC groups (group II and IV) were due to cardio-
vascular causes. Shorter dialysis time also was associated with
an increased number of hospitalizations due to cardiovascular
morbidity. Of 23 hospitalizations in the short-dialysis group
(groups III and IV), 17 (74%) were for cardiovascular causes,
whereas only 22% of the total hospitalizations were for cardio-
vascular causes in the long-dialysis-time groups (groups I and
II). Thus, although cardiovascular morbidity is not usually
attributed to inadequate dialysis, it became clear in the NCDS
study that higher TACurea and shorter dialysis time are associ-
ated with increased cardiovascular morbidity. This increase in
mortality occurred despite the absence of significant changes in
standard cardiovascular risk factors (such as cholesterol, tri-
glycerides, and heart size). The systolic blood pressure did
Td (C1 + C2) + 'd (C2 + C3)
2 (Td + Id)
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increase in the high-TAC, short-time group (group IV), but
only by a minor degree [10].
Gastrointestinal disorders also were more common in the
high-TAC1 groups (groups II and IV). Whereas only one of
the patients in the lOWTACurea groups (groups I and III)
required hospitalization (for elective gastrointestinal surgery),
14 patients in the high-TAC groups (groups II and IV)
required hospitalization for gastrointestinal disorders [12]. Gas-
trointestinal illnesses not requiring hospitalizations also were
more prevalent in the high-TAC groups [12]. Transfusion
requirements were higher and mean hematocrit lower in the
high-TAC groups [13]; mean values for sensory and motor
nerve conduction velocity progressively deteriorated in the
high-BUN, short-dialysis-time group (group IV) compared with
the lOWTACurea groups (groups land III) [14]. Thus, the NCDS
study clearly demonstrated that, compared with standard treat-
ment at the time of the study (4.5 hours, TACurea = 52 mgldl),
reduction of the efficiency of dialysis leads to a multiplicity of
adverse symptoms, which can persist even after a return to
"adequate" dialysis.
During experimental therapy (24 weeks), the mortality rate
did not significantly differ among these four groups. But in the
12 months after termination of the study—when patients were
returned to their conventional treatment—9 of 13 deaths (pre-
dominantly from cardiovascular and infectious causes) oc-
curred in patients previously enrolled in the high-TAC
groups (groups II and IV). This important observation suggests
that the effects of inadequate dialysis are not easily or quickly
reversed, even when the intensity and efficiency of dialysis are
increased.
More than a decade ago, Teschan and colleagues at Vander-
bilt University conducted another important study regarding
the adequacy of dialysis [15]. Using the observation that "few
if any patients display even the mildest uremic symptoms" at a
residual renal function of 10% of normal glomerular filtration
rate, Teschan proposed a minimum dialytic clearance equal to
10 mI/mm, or 100 liters/week. When this clearance was normal-
ized to the average volume of distribution of urea (total body
water), the target dialytic clearance became approximately 3000
mI/week/liter of body water. Therefore, for a regimen of 3
dialyses per week, a target of 1 liter of urea nitrogen clearance/
dialysis/liter of body water, or a "dialysis index" defined as
KT/V of 1 (K = dialyzer urea clearance at the specified blood
flow in mllmin, T = dialysis time in minutes, and V = volume
of distribution of urea in ml) was defined as "adequate" and
was utilized as a reference point. During an experimental
protocol lasting 6 months, in which patients were "underdia-
lyzed" with a total dialytic clearance of 2000 ml/weeklliter of
body water (equivalent to a KT/V of 0.66), Teschan and
colleagues studied a number of neurobehavioral variables and
administered a scored clinical self-evaluation questionnaire.
They identified manifestations of underdialysis from abnormal-
ities in the electroencephalogram (EEG)-tracing-derived "dis-
criminant score," a computer-derived composite index of ab-
normal EEG findings [15, 16]. In addition, these underdialyzed
patients exhibited deterioration of "continuous memory" (the
ability to recall whether a number has been previously dis-
played among 6 digits) and an increase in "choice reaction
time" (the time latency between random flashing of one of three
colors [red, yellow, or green light] and the selection by the
patient of one of two keys labeled "red" or "not red") [15].
Although these neurobehavioral variables, and the clinical
self-evaluation test scores, worsened significantly in all pa-
tients, "the patients continued to report their good health to
their doctors as well as their satisfaction with their shortened
dialysis time." Teschan also noted a decrease in predialysis
temperature, an increase in blood pressure, and an increase in
the number of transfusions during the experimental phase of
this study [15].
Both the NCDS and the Vanderbilt studies pointed out the
importance and the interrelationship of dietary intake, particu-
larly protein, and the adequacy of dialysis. During the experi-
mental phase of the Vanderbilt study, albumin concentration
significantly decreased [15]. More important, Teschan noted
that although urea clearance decreased by 33%, the urea
concentration rose only by 15% and interdialytic weight gains
declined; these findings suggested decreased food intake [15].
Similarly, in the NCDS study, patients in the high-TAC,
short-dialysis-time group (group IV) had the largest reduction in
dietary protein intake, as determined by calculation of protein
catabolic rate (PCR) [17]. In fact, a low PCR was second only to
a high TACurea in predicting drop-out and hospitalization rates.
In the final analysis of the NCDS study, all these parameters—
the TACUECa, the PCR, and dialysis time—have been combined
in contour plots that determine the "probability of failure" (as
defined by withdrawal for medical reasons, hospitalizations, or
death) in dialysis patients [11].
Which of these two parameters of urea removal, TACurea or
KT/V, is a better gauge of "optimal dialysis" for small mole-
cules? Using some simplifying assumptions, such as absence of
residual renal function, no change in weight between dialyses,
and constant interdialytic interval (dialysis every other day
rather than 3 times weekly), a mathematical relationship exists
between these two parameters, and calculation of one can be
made from measurement of the other [18]. To the extent that
these assumptions are not completely valid, however, I favor
the use of TACurea over KT/V. The major reason for this
preference is that TACurea incorporates the measurement of
interdialytic changes in urea nitrogen, from which protein
catabolic rate and dietary protein intake also can be calculated
[9]. As an aside, it should be emphasized that patient-recalled or
patient-recorded dietary intakes are not accurate [12]. The
assessment of adequacy of dialysis must include not only a low
TACUrCa, but a low TACurea in the setting of adequate dietary
intake, usually estimated by a dietary protein intake of at least
1 glkg/day. The patient presented today is an example of a man
with "acceptable" predialysis BUN levels but who was both
underdialyzed and slowly starving, as documented by his
considerable weight loss.
Use of the KT/V parameter is hampered by the fact that the
calculation of its components (K, T, V) depends on a host of
measurements, all subject to error [19]. Further, the errors most
often lead the clinician to overestimate KT/V and thus reduce
dialysis time. For example, K (the effective dialyzer clearance)
is often taken from in-vitro data, whereas in-vivo clearances
tend to be 15% to 20% lower in many dialyzers at the same
blood flow. In-vitro measurements also are typically given at
blood flows of 200 mI/mm, whereas most dialysis is now
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TAC(desired)
Td(desired) =
Td(cuffent)
Kd(cun-ent) X TAC(curreflt) X TCUfl
Kd(desired new time) x TAC(desired)
Table 2. Variables influencing dialysis prescription
Patient category Dialysis-related category
Residual renal function Interdialysis time
Volume of distribution Intradialysis time
Generation rate of "uremic toxin" Dialyzer clearance
Endogenous rate Area times permeability of
Diet the dialyzer
Access recirculation Biocompatibility-related
catabolic processes
Flow rate
Blood
Dialysate
Postdialysis urea rebound
Kd(cuiTent) X TAC(cupent)
=
Kd(desired, new time) X Td(desjred) (2)
This equation can be solved for either a new dialysis time
[Td(desred)] if one wishes to use the same dialyzer clearance as
shown in the following equation, or for a new dialyzer clearance
[Kd(desired)] if dialysis time remains constant.
performed at blood flows of 300 ml/min and higher in the case of
high-efficiency or high-flux dialyzers. Accurate in-vivo clear-
ance data generally are not readily available at these higher
blood flow rates [20]. Decreases in clearance toward the end of
a dialysis session due to dialyzer fiber occlusion also are not
usually considered. Most important, these clearances do not
take into account fistula recirculation, which is often in the
range of 15% to 20%, thereby resulting in a decrease in effective
clearance [21]. Recirculation also can increase at the higher
blood flows used today. Thus, in the patients dialyzed with
high-flux or high-efficiency dialyzers at blood flows up to 400
mI/mm, the effective clearance can be substantially less than
one calculated from blood measurements across a dialyzer [21].
Even dialysis time (Td) often is overestimated by nursing staff
as well as by the patient. The Td is the time of dialysis during
which the effective clearance of the dialyzer is applicable.
However, if the blood flow is not maximal from initiation of
dialysis, then the effective clearance, or effective time, is less
than calculated. Surveys of dialysis staff often indicate that the
Td is calculated from the time the patient has the needle inserted
until hemostasis is obtained. However, approximately 5% to
10% of this time passes in the absence of effective dialysis. The
volume of distribution of urea (V), often assumed to be a
constant ratio of total body weight, may not be so in all patients.
It can vary depending on body habitus and whether the weight
is measured before or after dialysis. Finally, calculation of
KT/V does not take into account residual renal function, which
can play an important role in the adequacy of dialysis of
small-molecular-weight substances. Although calculation of
KT/V globally (rather than its components) can be made from
the difference between pre- and post-BUN, and would reduce
these potential errors, this type of calculation requires more
complex mathematical manipulation.
Calculation of TACurea primarily depends on pre- and post-
dialysis urea nitrogen values and is less subject to such errors.
However, the BUN level immediately after dialysis can be 5%
to 10% lower than that 30 minutes later, because of re-
equilibration between the vascular and intracellular pools [22].
The extent of this rebound increases as dialysis efficiency (more
urea clearance per unit time) increases. This is particularly
applicable to high-flux and high-efficiency dialysis regimens.
What should the target TACurea be for optimal dialysis? As
pointed out recently, we must move beyond the question of
adequacy to questions of optimal dialysis dose [23—25]. The
answer to this question clearly has two components. What is
the acceptable risk or failure rate, and what is tolerable for
patients who need to undergo this treatment three times
weekly? The NCDS contour plots, representing the probability
of failure as a function of TAC and PCR, can provide an answer
[10, 18]. If a probability of failure of 10% is acceptable for
"adequate" dialysis, and assuming protein intake of 1 g/kg/day
and a dialysis time of 4 hours per session, a TACurea of around
50 mgldl is the target. To achieve a failure rate of substantially
less than 10%—that is, optimal dialysis by my definition—may
require even lower TACurea, again, in the setting of adequate
nutrition. Changes in TACurea are a function of patient-depen-
dent and patient-independent variables (Table 2) and, once
determined, can be easily achieved by changes in dialysis time,
or dialytic clearance according to the following formula:
(3)
Two groups recently re-analyzed the NCDS data. On the
basis of a discontinuous distribution of probability of failure and
KT/V values in the NCDS study, Gotch and Sargent have
advocated a threshold KT/V of greater than 0.8 at a protein
catabolic rate of greater than 0.8 g/kg/day for adequate therapy
[26]. More recently, re-analysis of edited data from the NCDS
by Keshaviah and Collins indicated that participating patients
had a continuous distribution of KT/V [27]. By extrapolating
the linear relationship of KT/V with the probability of failure,
they concluded that failure is negligible once KT/V reaches
approximately 1.3. Although the linear dependence of failure
rate to KT/V is somewhat controversial (as I just mentioned,
Gotch and Sargent have advocated a KTIV greater than 0.8 as
a threshold value), the evidence for a continuous relationship
between higher KT/V and lower failure rate is, in my estima-
tion, more compelling.
Does optimization of dialysis (with utilization of KT/V values
of greater than 1) affect patient mortality, the ultimate compli-
cation of dialysis? Most of the evidence available to examine
this question is circumstantial and depends on comparisons of
mortality rates for patients in different settings. Retrospective
analysis of two groups of hemodialysis patients has shown that
patients dialyzed for prolonged periods do indeed have a lower
mortality rate. In France, a group of 373 patients, including 63
"high-risk" patients dialyzed for 22 to 24 hours/week (at night),
had an overall 10-year survival of 75%—an annual mortality of
2.5% [28]. In the U.S., a group of 362 hemodialysis patients
without major systemic illnesses were reported to have a 5-year
survival of 84% (annual mortality of 3.2%), and an average
hospitalization rate of approximately 10 days per patient per
year [29]. A retrospective analysis of the dialysis prescription in
this group showed that they had a KT/V of between 1.2 and 1.4
[24].
In sharp contrast, the national annual mortality rate of the
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Table 3. Annual mortality rate of ESRD patients in different
countries
Mean age
(yrs)
% All
patients
>65 yrs
% New
enrollees
>65 yrs
Gross
mortality
(%)
EDTA — 15.8 — 10.4
W. Germany 58.0 22.6 30.7 11.0
France 57.0 18.8 31.7 7.8
Sweden 59.0 21.7 37,0 14.7
New Zealand — — — 14.2
Australia — — — 13.6
Canada — — — 16.9
Japan — 10.1 30.0 8.7
USA 55.5 26.0 35.5 22.8
dialysis population in the United States is rising, from 20.6% in
1979 to 23.4% in 1987, despite major advances in dialytic
techniques (volumetric control of ultrafiltration, bicarbonate
dialysate, and safer heparinization) [30]. This mortality rate is
considerably higher than the average annual mortality of 10.4%
in European countries [311. The end point of the survival
calculation in the European data was either death or date of
change to another treatment mode, such as peritoneal dialysis
or transplantation. Thus, actual mortality is likely even lower.
Neither the mean age of the dialysis patient (55.5 years in the
United States, 57—59 in different European countries) nor the
percentage of new patients over 65 years of age (35.5% in the
U.S., 31% in West Germany, 37% in Sweden) accounts for all
of this difference (Table 3). However, a marked difference in
dialysis times between the U.S. and other countries does exist.
Whereas in the United States the average dialysis time is 9
hours per week, in Europe the average is 12 hours per week and
in Japan it is 15 hrsfweek. Furthermore, missed dialyses and
"signing off early" decrease the cumulative dialysis dose even
further in the U.S., whereas in Europe signing off early is much
less common (personal communication, Dr. Allan Hull).
Other studies have also shown that relative risk of mortality,
both from cardiovascular and non-cardiovascular causes, was
significantly higher for patients dialyzed twice a week compared
with those dialyzed three times a week [32]. The former group
also had lower body-mass index and cholesterol concentration,
consistent with malnutrition. Interestingly, there was no differ-
ence in predialysis urea concentration between the groups [32].
Uncontrolled studies of long-term (>10 years) dialysis have
shown that survivors have consistently been patients dialyzed
for extended periods [33, 34].
A somewhat more direct confirmation of the impact of the
dialysis prescription on mortality was presented at the Ameri-
can Society of Nephrology meeting in 1988. The data from
Dumler and associates support the notion that the relative risk
of mortality is significantly higher when the KT/V is less than
0.8 and when the PCR is less than 0.8 glkglday [35]. In another
study of 650 patients, the relative risk of mortality was 2.0 when
dialysis time was less than 3 hours, 30 minutes, and risk was
significantly lower in units practicing kinetic modeling [361.
In conclusion, kinetic modeling provides a reasonable guide-
post for measuring the adequacy of dialysis. If one believes that
we should "above all, do no harm," we must aim for a KT/V of
1.2 to 1.3 or a TACurea of less than 50 mg/dl, in the setting of a
dietary protein intake of approximately 1 g/kglday. Understand-
ing and applying these concepts is particularly important in this
era of "short-time" dialysis.
132 microglobulin removal
The patient under discussion had a second set of problems
that confront nephrologists caring for patients on long-term (>5
years) dialysis: elevated serum f32-microglobulin (132m) levels,
carpal tunnel compression syndrome, and, occasionally, radio-
logic evidence for amyloid bone disease. The clinical manifes-
tations of inadequate removal of f32-microglobulin, a protein
with a molecular weight in the range of 11,800 daltons (there-
fore, a "middle molecule"), are more prevalent and recognized
more often in long-term dialysis patients [37]. Deposition of
amyloid fibrils that consist of intact f32m polymers has been
recognized in dialysis patients only since 1985 [38, 39], and the
association of these fibnis with carpal tunnel syndrome is now
well recognized [40, 41]. We now know that /32m amyloid
deposits in bone and produces a newly recognized type of
osteoarthropathy characterized by progressively enlarging cys-
tic radiolucent lesions without surrounding sclerosis [37, 42,
43]. Although the radiologic findings in some patients are
unambiguous, histologic examination of biopsy material often is
required for definitive diagnosis. Clinically, f32m amyloid ar-
thropathy can produce pain, noninfiammatory swelling, and
dysfunction of joints, and can result in pathologic fractures,
particularly if it involves the femoral head and neck [43]. The
pathogenesis of this disorder is not well understood; all dialysis
patients without residual renal function have elevated serum
levels of /32m, the precursor of this novel type of amyloid bone
disease [44]. Although initial reports suggested that the type of
dialysis membrane has no role in the development of the
disease, recent studies document that the lowest levels of f32m
occur in patients dialyzed with large-pore (high-flux) hemodial-
ysis or hemofiltration membranes, probably because these
membranes allow convective, diffusive, and possibly adsorp-
tive clearance of j32m [45—48]. A potential role for cuprophane
membranes, associated with complement activation [49] and
monocyte activation [50] in the increased generation of 132m
also has been proposed [51—53]. In patients chronically dialyzed
with large-pore membranes, the incidence of amyloid bone
disease is much less than in those dialyzed with cuprophane
membranes. Indeed, a recent study pointed out that none of the
patients dialyzed solely with the polyacrylonitrile membrane for
as long as 15 years developed carpal tunnel syndrome, whereas
6 of 20 patients dialyzed with cuprophane membranes for 10
years had evidence of carpal tunnel syndrome [54]. Thus, the
use of biocompatible, larger-pore membranes such as the poly-
acrylonitnle or polysulfone might prevent (or considerably
retard) the development of carpal tunnel syndrome and /32m
amyloid bone disease by allowing a higher rate of removal, a
decreased rate of synthesis, and a lower serum level of /32m
[55—57]. I believe that in the near future, adequacy of dialysis
will be defined not only by efficient removal of urea, but also by
the efficient removal of 132 microglobulin [58].
A recent study has suggested that the determination of the
adequacy of dialysis using KT/V (and urea as a surrogate small
molecule) and protein catabolic rate as an index of nutrition
might not be independent of the type of dialyzer membrane
used. Dialysis by more biocompatible and larger-pore mem-
branes (such as the polyacrylonitrile or polysulfone membrane)
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that have higher clearances for middle molecules might require
a lower dialysis dose than hemodialysis by cellulosic membrane
[59]. This hypothesis, which needs confirmation, might provide
a link between the two issues of urea and f3,m removal, an issue
that has not been well explored so far.
I conclude that many of the long-term complications of
hemodialysis patients are preventable, and that adequacy of
dialysis must be defined by removal both of small-molecular-
weight (for example, urea) and high-molecular-weight (for ex-
ample, /32m) substances. As our understanding of the pathogen-
esis of these complications improves, we not only can provide
patients with adequate dialysis but with optimal dialysis that
offers them a long, healthy survival.
Questions and answers
DR. JOHN T. HARRINOTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): You spent a
great deal of time discussing the National Cooperative Dialysis
Study. That study was published in 1981, so the study itself
must have taken place in the late 1970s. By that time studies by
Teschan [60] and studies by Kiley [61] in Albany had demon-
strated that the incidence of uremic electroencephalographic
abnormalities statistically was related to prevailing levels of
urea nitrogen and creatinine. Given that information, what was
the rationale for dialyzing patients who had BUNs of 100 to 120
mg/dl? Admittedly, I am looking at the results of the NCDS in
retrospect. Trying to argue from the vantage point of 1977 to
1979—with the information available at that time—I think one
might have predicted that group IV would do the worst.
DR. HAKIM: The rationale of the NCDS and its evolution
from the early workshops of the Artificial Kidney-Chronic
Uremia Program (AKCUP) of the National Institutes of Health
was well outlined by Dr. Wineman (program director and
project officer of that study) [62]. In summary, the study design
and the protocol were based on several multidisciplinary con-
ferences that started as early as 1972 [3]. The final protocol was
developed in December 1974. Dr. Kiley's article, published in
1975 [61], advocated that dialysis therapy be carried out three
times weekly, rather than twice weekly, and work by Teschan,
Ginn, et al in 1979 did not define at that time a specific target
urea [60]. It is fair to say that in 1974 neither a target urea
concentration nor the timing of sampling (pre- or post-dialysis,
mid-week, or early in the week, etc.) was well known, nor
indeed whether urea was the target molecule to be evaluated.
The most common index of dialysis at that time was based on
the square meter-hour hypothesis [63] and dialysis index [7],
which assumed that materials in the 1000 to 3000 dalton range
(rather than urea) were what caused the neurotoxicity of
uremia. It is also important to keep in mind that even for group
IV, whose average TACurea during the experimental period was
93.6 mg/dl, the mid-week pre-dialysis BUN was 115 9 mg/dl,
a value that is still encountered in many dialysis patients; in
fact, the TACurea of group IV (which can be considered as
equivalent to the ambient urea level of chronic renal failure
patients) was still lower than what some nephrologists, even at
present, would consider as guideposts for initiation of hemodi-
alysis.
DR. ANDREW S. LEVEY (Division of Nephrology, New En-
gland Medical Center, Boston, Massachusetts): Do you think
the newer dialysis machines that can precisely control ultrafil-
tration and the rate of fluid removal, as well as those that yield
higher clearances, result in better treatment both in the short
term and long term?
DR. HAKIM: Unquestionably, the technologic advances in
dialysis therapy helped improve the frequency and severity of
intradialytic and interdialytic symptoms. The widespread use of
bicarbonate instead of acetate as the base in the dialysate
clearly has led to a reduction in the incidence of nausea,
vomiting, and hypotension [64]. The introduction of precise
ultrafiltration systems and sodium modeling also has allowed
the gradual and controlled reduction of plasma water to within
0.2 kg of target and has led to a reduction in the incidence of
cramps and hypotension. Finally, the use of so-called "high-
flux" and "high-efficiency" large-surface-area dialyzers has
allowed consideration of shorter dialysis sessions. However, it
is precisely in these situations where kinetic modeling and the
determination of adequacy of dialysis become even more im-
portant. The shorter the dialysis time, the less the margin of
safety in the delivery of adequate dialysis. A reduction of 15
minutes in dialysis time or a reduction of 10% in the clearance
of a dialyzer is relatively more important when the prescribed
dialysis time is 3 hours or when the assumed clearance is 300
mllmin than when one is dealing with the usual 4-hour dialysis
and 200 mi/mm urea clearance. In the setting of high-flux
dialyzers, higher dialytic clearances at higher blood flows can
only be achieved if recirculation in the access is low [211.
Similarly, although one can achieve much higher ultrafiltration
rates with these newer dialyzers, there is still limitation on the
rate at which these can be tolerated, and adverse symptoms
increase exponentially as rates of ultrafiltration exceed 1.2
liters/hr [65].
DR. JEROME P. KAS5IRER (Associate Physician-in-Chief,
New England Medical Center): You indicated that a correlation
exists between increasing mortality rate and shortened time on
dialysis. Can you elaborate on a possible causal link between
the two?
DR. HAKIM: The correlation I meant to emphasize in the
discussion of the case is between increasing mortality rate and
inadequate or inappropriately short dialysis time. These corre-
lations are primarily based on retrospective studies and include
the studies by Laurent [28], Shapiro [291 and, more recently, by
Dumler [351 and Levin [36]. The first two studies showed that
prolonged survival is associated with long dialysis; the other
two studies, so far in abstract form, have shown the inverse,
that is, that patients who receive inadequate dialysis (KT/V <
0.8) have a higher mortality rate. At the time the study by Levin
was undertaken, no high-flux or high-efficiency dialyzers were
available, and the study clearly showed that patients dialyzed
less than 3.5 hours had a higher mortality rate. During the
experimental period of the NCDS study (52 weeks), there was
no difference in the mortality rate of patients among the 4
groups, but within one year after returning from experimental
therapy to routine dialysis, 13 of the participating patients died,
10 of whom were in the high-TAC1 groups (II and IV) [171.
Specific causes of mortality in these patients included predom-
inantly cardiovascular and infectious causes. The causal links
of the pathophysiology relating inadequate dialysis to cardio-
vascular risk factors are speculative and include arrhythmia
from hyperkalemia, congestive heart failure, and hypertension
from inadequate removal of volume leading to exacerbation of
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coronary artery disease. The link between infection and inade-
quate dialysis time probably relates to the generally deleterious
effects of uremia and malnutrition that result from inadequate
dialysis on neutrophil and immune functions [66].
DR. NICOLAOS E. MArMAS (Chief, Division of Nephrology,
New England Medical Center): Were the patients in the NCDS
study stratified according to intensity of dialysis prior to the
initiation of the study, or according to other variables of
morbidity, such as cardiovascular history and diabetes melli-
tus?
DR. HAKIM: Prior to randomization, more than 50 variables
were analyzed to determine whether any significant baseline
differences existed among the 4 experimental groups. This
analysis showed that, with few exceptions, the demographic
and medical profiles of the 4 groups were quite similar prior to
randomization. Only 6 of 50 variables showed marginal statis-
tical significance, and the clinical impact of these differences
was judged to be minimum. In any event, all statistical analysis
of the experimental phase data were adjusted for control phase
values [17].
DR. DAVID B. BERNARD (Director, Clinical Nephrology,
Boston University Medical Center): With regard to Dr. Har-
rington's question about the rationale of the NCDS having
included a high-BUN group, I presume the reason was that the
investigators were not, regarding BUN as a toxin per se and
were examining its reliability as a marker of uremic "toxins" in
general. Theoretically, a group of dialyzed patients might have
been identified who had high BUNs yet still did well because
other toxins, such as "middle molecules," were being ade-
quately removed by the various experimental modifications in
the dialysis prescription.
DR. HAKIM: Yes, that is correct. As I stated earlier, the
protocols of the NCDS study were finalized in 1974. The
relevance of the numerous biochemical abnormalities in uremic
serum, detected by increasingly sophisticated laboratory meth-
ods, to the clinical illness called "uremia" was not clear then,
and even at present is not well established. I think this uncer-
tainty was another reason for deciding on group IV.
DR. BERNARD: I have another question about the conclusions
of the NCDS. All studies were done on cellulosic dialysis
membranes, so how certain can we be that the findings are
applicable to today's generation of largely synthetic mem-
branes? A TACurea of 50 achieved on a polyacrylonitrile mem-
brane, for example, might not adequately remove other poten-
tial toxins having molecular weights different than that of urea.
This point has been made previously [67]. Is this of sufficient
importance to justify a further study?
DR. HAKIM: I would strongly favor such a study. At the time
the NCDS study was ongoing, only cuprophane or regenerated
cellulosic membranes were available; neither bicarbonate dial-
ysate nor controlled ultrafiltration devices were available. The
newer synthetic membranes with larger pores and higher clear-
ances of substances in the "middle molecule" range indeed
might change the parameters of dialysis adequacy, whether
KT/V, TACurea, or PCR. Indeed, in a recent article, Lindsay
proposes that possibility and suggests that the use of large-pore
synthetic membranes might allow the safe delivery of a lower
dialysis dose [59]. My plea is that until this study is done, we
should use what we know in assessing the adequacy of dialysis.
DR. BERNARD: I have a question about dialysis-associated
amyloid disease. Some years ago, we studied several specimens
of tissue removed at surgery for carpal tunnel syndrome and
stained for amyloid. Surprisingly, relatively few—about 20%—
stained positively. Does this mean that special staining tech-
niques or specific antibodies are needed to demonstrate the
presence of this form of amyloid material, or that causes of
carpal tunnel syndrome other than amyloid deposition exist in
these patients? Should we not assume that these cases are all
amyloid related? What is your experience in this regard?
DR. HAKIM: The incidence of amyloid fibrils in the dialysis-
associated carpal tunnel syndrome (CTS) is reported in the
literature to range from 0% to 100% [58]. Our own experience
suggests that it is present in more than 50% of the patients
presenting with CTS. I suspect the major factor involved in the
wide range of these reported incidences is the small series of
patients and the variable length of time these patients have been
on dialysis. As you know, the incidence of CTS and other
manifestations of 2m amyloid deposits increases with dialysis
time. Recent evidence suggests that it is particularly prevalent
in long-term dialysis patients dialyzed with cuprophane mem-
branes, and less so in patients dialyzed with the polyacryloni-
trile or similar other synthetic membranes [54, 58].
DR. BERNARD: My final question! Based on the clearance of
f32-microglobulin across the peritoneal membrane, can you
predict whether patients on CAPD are prone to a similar risk of
dialysis-associated amyloid disease?
DR. HAKIM: The clearance of /32-microglobulin across the
peritoneal membrane has been reported to be 0.9 0.4 ml]
min/! .73 m2 and the mean loss of 132-microglobulin was approx-
imately 20 mgI2 liter exchange [68]. In general, the level of
J32-microglobulin in CAPD patients is 70% of that in hemodial-
ysis patients, and there have been few reported cases of
amyloid fibrils in CTS of CAPD patients [69]. However, a
recent report suggests that the incidence of CTS in patients
undergoing peritoneal dialysis (14%) is only slightly less than
that in hemodialysis patients (18%) [70]. It is possible that other
factors (frequency of peritonitis, dialysate pH, etc.) affect these
reported results. In addition, dialysis-associated amyloid dis-
ease is a disease of long-term dialysis patients, and few centers
have large series of patients on long-term peritoneal dialysis.
Therefore it is difficult to arrive at a specific incidence in these
patients. What is clear is that peritoneal dialysis is not a therapy
for the complication of high /32-microglobulin levels in dialysis
patients.
DR. RONALD D. PERRONE (Division of Nephrology, New
England Medical Center): Could you bring us up to date on
other markers of the uremic state? Is there any information on
more direct measurements of altered cell metabolism, such as
sodium-potassium-ATPase? Has anything been done to make
such measurements useful clinically?
DR. HAKIM: Several candidate molecules that accumulate in
chronic renal failure have been proposed to explain the uremic
state. These range from parathyroid hormones [71] to indoles,
phenols, and polyamines [72]. It is fair to say that although all
these putative molecules alter cellular activity in one way or
another, and mimic in animal experiments some uremic symp-
toms, almost all of these studies have been tested in acute
toxicity conditions, with little attention paid to intracellular
concentrations, synergy, or tachyphylaxis [721. Our inability to
quantitate indices of the disabling "uremic illness" plays a role
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in this confusion. I believe that the quantitative probes of the
nervous system function proposed by the studies of Teschan
[60] so far present the best assessment of the clinical illness of
uremia. The task, difficult as it is, is to develop these indices
and attempt to correlate them with specific biologic parameters.
DR. KASSIRER: Anemia could produce symptoms in patients
with advanced renal failure. Has anemia been factored out as
one of the important features that cause substantial disability?
We should have some information on this issue now that
synthetic erythropoietin is being made available.
DR. HAKIM: The advent of erythropoietin (EPO) in combina-
tion with biocompatible dialyzers and the other technologic
advances discussed earlier indeed might force us to change our
perception of what the 'uremic" state is and the disabilities
that may be associated with it. Reports have appeared on the
biologic effects of EPO [73, 741, and there are a number of
abstracts on the symptomatic changes experienced by dialysis
patients with EPO; it is clear that patients' fatigue as well as
their well-being and sexuality are improved with the use of EPO
[75, 76]. However, its long-term effects on morbidity and
mortality are not yet known. Nevertheless, I think the issue of
the adequacy of dialysis will be more important with the advent
of EPO because the net clearance of urea, potassium, and
phosphate is likely to be reduced to a variable extent in patients
on EPO, depending on the respective distribution of these
substances in intracellular and extracellular spaces.
DR. HARRINGTON: I am struck by the remarkable difference
in mortality between the United States, almost 25%, and
Europe, roughly 10%. You mentioned the difference in dialysis
time. What other factors might play a role in the difference in
mortality rates? My own bias is that the difference relates to
comorbid events. Are there data on specific differences in the
prevalence of comorbid conditions such as diabetes or ischemic
heart disease?
DR. HAKIM: Unfortunately no data on comorbid events are
uniform enough to be comparable between different countries,
such as the United States registry and the European registry.
Each country has a different way of providing dialysis-related
information. However, even in the younger age group (less than
34 years), there is a major difference in mortality. For patients
less than 34 years, the annual European mortality is 6%,
whereas in the United States, it is 12.7% [31]. Dr. Allan Hull,
who was kind enough to share a manuscript he is preparing on
this issue, suggests in that manuscript that neither differences in
age nor prevalence of diabetes can account for these differ-
ences. Instead, he suggests that dialysis time, which is longer in
Europe (12 hrs/week) and in Japan (15 hrs/week) than in the
United States (9 hrs/week), might be a factor. One of my own
biases is that this difference in mortality may be partly due to
the use of non-biocompatible (predominantly cuprophane)
membrane in the U.S., whereas in Europe and Japan, the use of
biocompatible dialysis membranes is much more common.
DR. MADIAS: How does dialyzer reuse affect the adequacy of
dialysis?
DR. HAKIM: For cuprophane dialyzers, if the residual fiber
bundle volume of the dialyzer is greater than 75% of the original
volume (which is the standard cut-off for reuse), the clearance
and ultrafiltration characteristics are not significantly affected;
therefore, cuprophane dialyzer reuse should not affect the
adequacy of dialysis [77]. No such data are available for the
more open pore structure" of the high-flux membranes, and it
is important to get this information.
DR. HARRINGTON: I have two questions. First, how often do
you calculate TACurea nitrogen and make alterations based on
the results? Second, in patients with carpal tunnel syndrome,
where else in the body does the f32-microglobulin deposit, and
does it contribute to disease elsewhere?
DR. HAKIM: These are two important questions. The first
addresses the practical steps in the determination of the ade-
quacy of dialysis. We determine fistula recirculation during the
initiation of dialysis on every patient or whenever we are using
a new access for the first time to get a "baseline" value. We
also start every patient on 4 hours of dialysis, because it is much
easier to reduce dialysis time than to increase it. We do kinetic
modeling using "pre-, post-, and pre-BUN," and determine
endogenous residual renal function, if present, within one
month of initiation of dialysis. We then calculate TACurea and
KT/V and PCR from these data. Because residual renal function
decreases rapidly after the first few months on hemodialysis, we
use this initial kinetic modeling data as an index to make sure
patients are not underdialyzed. We repeat all measurements
quarterly and aim to keep KT/V at 1.2 and TACurea at 50 mgldl.
Under these conditions, PCR often rises gradually to at least 1.0
g/kg/day. If KT/V is less than 1.0, we will increase dialysis time,
increase dialytic clearance (by using large-surface-area dialyz-
ers), or, if recirculation is greater than 20%, correct the recir-
culation problem by revising the arteriovenous fistula.
DR. HARRINGTON: Do you know specifically whether /32-
microglobulin deposits in heart valves or in the myocardium?
DR. HAKIM: The extent of extraskeletal soft tissue involve-
ment by p2-microglobulin-related amyloidosis appears to be
much less than its involvement with the skeletal system [58],
but autopsy reports have documented the presence of /32-
microglobulin amyloid deposits in vascular tissue including the
heart, although I am not sure they specifically address the issue
of cardiac valves. It is important to know that there are several
types of amyloidosis related to different types of paraproteins.
The diagnosis of f32-microglobulin amyloidosis should be made
not only by the classic birefringence, but by the sensitivity of
the tissue staining of Congo red to potassium permanganate,
and more directly by its uptake of antibodies to /32-microglob-
ulin.
DR. KLEMENS MEYER (Fellow in Nephrology, New England
Medical Center): As you mentioned, cardiovascular disease is a
major source of comorbidity in dialysis patients. Suppose one
compares well-dialyzed patients with the rest of the population.
Do aggressive attempts to prevent or treat coronary disease
have more effect, less effect, or comparable effects in those two
groups?
DR. HAKIM: If one is comparing cardiovascular morbidity
between well-dialyzed and poorly dialyzed patients, then, as
the NCDS has shown, the incidence of cardiovascular morbid-
ity is much higher in the poorly dialyzed patients [10]. There-
fore, optimal dialysis will prevent or reduce the incidence of
cardiovascular events. As far as whether the treatment of
coronary artery disease is less or more effective in the dialyzed
patients, I do not have the data, but I suspect the answer is yes,
because a well-dialyzed patient is also one who can respond
better to interventions.
DR. GEETHA NARAYAN (Division of Nephrology, St. Eliza-
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beth's Hospital, Boston): You commented that TACurea might
be a better way of measuring the adequacy of dialysis than is
KT/V. We have made observations in some of our patients on
high-flux dialysis that suggest the same. Our patients have
KT/Vs in the "adequate" range by current accepted standards,
along with adequate PCRs. Yet they have mid-week pre-
dialysis BUNs higher than what you would predict from the
given KT/V and PCR. Could this discrepancy be due to the
rapid rebound in BUN within minutes of completing dialysis
that you referred to earlier? In all patients, the dialysis time is
charted by the dialysis clock, not the wall clock, and inadequate
dialysis due to compromised time would not be a factor.
DR. HAKIM: Recirculation might be the culprit in this situa-
tion. Using high-flux dialyzers at high blood flow rates will
increase the percentage of recirculation and decrease effective
dialytic clearance [21]. If one uses calculated or in-vitro clear-
ances, a patient can have adequate KT/V but inadequate
measured TACurea value and high mid-week BUN. A hint to
that problem can be found if the calculated volume of distribu-
tion of urea is higher than expected (> 0.65 of body weight).
The extent of rebound in urea concentration following termina-
tion of dialysis has been recently shown to be higher the greater
the dialytic clearance. In the case of high-flux dialyzers, the
rebound in urea concentration immediately post dialysis can be
8% to 10% [22].
DR. NARAYAN: We have been using blood flows of only 350
to 400 mllmin. We have calculated recirculation in many of
these patients, and it has not been excessive. The post-BUN
value that we are measuring, before rebound, might be lower
than the value after rebound, so could it be that the calculated
KT/V overestimates the actual dialysis delivered? Could that
explain the higher mid-week BUN levels we are seeing? Per-
haps we should be using a double-pool urea model instead of the
single-pool model currently used.
Da. HAKIM: Both post-dialysis BUN rebound and access
recirculation could account for this difference. As far as using a
double-pool model for urea, it should be considered only if the
dialytic clearance approaches the clearance of urea from intra-
cellular to extracellular spaces. This is estimated to be approx-
imately 600 mI/mm, although substantial individual variations
exist; urea double-pool models, which add considerably to the
complexity of the calculation, do not need to be considered at
currently available dialytic clearances.
DR. JEANINE CARLSON (Chief of Medicine, St. Margaret's
Hospital, Boston): The data presented in your slides demon-
strate a correlation between morbidity and TACurea. Although it
will vary from patient to patient, we don't usually institute
dialysis until their BUN is in the range of 100 to 200 mgldl,
which is higher than any of the TACurea levels I saw on your
slides. Would you comment on when you begin dialysis?
Specifically, do you think it would be beneficial to our patients
if we started sooner?
DR. HAKIM: Many patients with chronic renal failure deny
symptoms until their BUN is at the levels you mentioned, and
patients and physicians are often reluctant to start dialysis in
the absence of uremic symptoms. My own feeling is that
patients are generally apprehensive of dialysis and tolerate or
adjust to increasing incapacitation. Patients also spontaneously
self-restrict their protein intake with advancing renal failure;
therefore their BUN does not reflect the degree of renal
insufficiency [78]. Dialysis therefore is initiated in many pa-
tients after loss of greater than 10% of body weight. On the
other hand, work by Shemesh has clearly shown that serum
creatinine is a poor reflection of true GFR [79]. Thus, what we
have adopted in our clinical practice is the idea of determining
true GFR by 125! iothalamate. We prepare patients' access
when the GFR is less than 15 ml/min, and we initiate dialysis
when the GFR is less than 10 ml/min or if the patient loses more
than 5% of body weight. For many patients dialysis is a lifelong
commitment, so this preparation must be accompanied by a
strong emphasis on compliance, because patients who do not
"feel" sick prior to initiation of dialysis may be less likely to be
convinced that they need dialysis three times per week.
DR. LEVEY: If the TACurea in a patient on pentoneal dialysis
is 50 mg/dl, it is likely that the protein catabolic rate can't be as
high as 0,8 glkg/day. In fact, that protein intake is only 70% to
80% of the recommended dietary protein intake for such
patients. Thus we are forced to the conclusion that the average
BUN for patients on peritoneal dialysis ought to be about 80
mg/dl. In fact, that is the range I aim for in my practice. My
patients who are doing well and eating well do have BUNs in
the 80s. How does that observation square with the notion that
urea is a good marker for the toxic substance that determines
dialysis adequacy?
DR. HAKIM: The weekly dialytic clearance by peritoneal
dialysis is generally two-thirds what hemodialysis can deliver.
The reasons pentoneal dialysis patients do not have higher
TACurea levels are several. In the first place, many patients
initiated on peritoneal dialysis retain their residual renal func-
tion for longer periods; second, many peritoneal dialysis pa-
tients generally do not eat a lot of protein, because they have
early satiety from the calories they receive from dialysate
glucose. Many peritoneal dialysis patients are in fact protein
malnourished, and I believe that this, along with the protein loss
in the dialysate, might account for the high incidence of
peritonitis and the generally low BUN that they have despite
reduced dialytic clearance. As far as what target urea to aim for,
I would suggest that until we have a study to monitor the
adequacy of dialysis in peritoneal dialysis patients in terms of
urea concentration, the emphasis should be on a PCR of greater
than 0.8 g/kglday; the frequency of exchange should be adjusted
to allow as low a TACurea as practical in this setting.
DR. MICHAEL P. MADAIO (Division of Nephrology, New
England Medical Center): Is the incidence of amyloidosis
dependent on the type of membrane you use? I ask that
question because it is well known that different membranes
have different effects on the immune system.
DR. HAKIM: There was some confusion about this issue in the
initial studies because the studies compared patients who were
on one or another type of membrane for a relatively short
period and because patients in different groups were not
matched for residual renal function, a major determinant of
132-microglobulin serum concentration [68]. Subsequently,
other studies have shown that patients who have been on
hemodialysis using synthetic membranes, such as the polyacry-
lonitrile (PAN) membrane, have a significantly lower level of
/32-microglobulin and a lower incidence of amyloidosis than do
patients dialyzed with the cuprophane membrane [54]. The
question that is being investigated at present is whether this is
only due to the ability of the synthetic membrane to absorb or
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clear /32-microglobulin or whether the cuprophane membrane,
which is well known to elicit a number of inflammatory re-
sponses, plays a role in the increased synthesis of /32-micro-
globulin [52]. In our laboratory, preliminary work suggests that,
indeed, mononuclear cells harvested from patients dialyzed
with cuprophane membrane have a significantly higher rate of
/32-microglobulin release than when the cells are harvested
during the time the patients are dialyzed with a biocompatible
membrane. However, this remains to be confirmed. Finally,
although many long-term dialysis patients have elevated 132-
microglobulin, the triggering factor(s) that lead this substance to
form into amyloid deposits in skeletal sites is not known [80,
81].
Reprint requests to Dr. R. Hakim, Division of Nephrology, Vander-
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Acknowledgments
The author would like to thank Drs. William Stone, Gerald Schul-
man, P. Kesheviah, and Thomas Parker for valuable input and discus-
sion; Dr. Thomas Parker for the use of Table 2 and equations (2) and (3);
and Dr. Allan R. Hull for the use of Table 3.
References
1. Lowsu EG, LAIRD NM, PARKER TF, SARGENT JA: Effect of the
hemodialysis prescription on patient morbidity. Report from the
National Cooperative Dialysis Study. N EnglJ Med 305:1176—1181,
1981
2. LOWRIE EG, LAIRD NM (eds): Cooperative Dialysis Study. Kidney
mt (suppl 13) 23:S1—S122, 1983
3. GOTCH FA, KRUEGER KK (eds): Adequacy of dialysis. Kidney mt
(suppl 2) 7:S1—S263, 1975
4. GOTCH FA: A quantitative evaluation of small and middle molecule
toxicity in therapy of uremia. Dial Transplant 9:183—192, 1980
5. SARGENT JA: Control of dialysis by a single-pool urea model: The
National Cooperative Dialysis Study. Kidney mt (suppl 13) 23:
S19—S25, 1983
6. FROST TH, KERR DNS: Kinetics of hemodialysis: A theoretical
study of the removal of solutes in chronic renal failure compared to
normal health. Kidney mt 12:41—50, 1977
7. 13B AL, STRAND MJ, UVELLI DA, MILUTIN0vIc J, SCRIBNER
BH: Quantitative description of dialysis treatment: A dialysis
index. Kidney mt (suppl 2) 7:S23—S29, 1975
8. SCHREINER GE: The search for the uremic toxin(s). Kidney mt
(suppl 3) 7:S270—S275, 1975
9. BORAH MD, SCHOENFELD PY, GOTCH FA, SARGENT JA, WOLF-
SON M, HUMPHREYS MH: Nitrogen balance during intermittent
dialysis therapy of uremia. Kidney fin 14:491—500, 1978
10. HARTER H: Review of significant findings from the National Coop-
erative Dialysis Study and recommendations. Kidney mt (suppl 13)
23:S107—S112, 1983
11. LAIRD NM, BERKEY C, L0wRIE EG: Modeling success or failure of
dialysis therapy: The National Cooperative Dialysis Study. Kidney
mt (suppl 13) 23:Sl01—Sl06, 1983
12. SCHOENFELD PY, HENRY RR, LAIRD NM, ROXE DM: Assessment
of nutritional status of the NCDS population. Kidney mt (suppl 13)
23:S80—S88, 1983
13. SANTIAGO G, RAO TKS, LAIRD NM: Effect of dialysis therapy on
the hematopoietic system: The National Cooperative Dialysis
Study. Kidney mt (suppl 13) 23:S95—S100, 1983
14. TESCHAN PE, B0URNE JR, REED RB, WARD JW: Electrophysio-
logical and neurobehavioral response to therapy. The NCDS Study.
Kidney mt (suppl 13) 23:S58—S65, 1983
15. TESCHAN PE, GINN HE, BOURNE JR, WARD JW: Neurobehavioral
probes for adequacy of dialysis, Trans Am Soc Artf Intern Organs
23:556—560, 1977
16. HUGHES JR: Correlations between EEG and chemical changes in
uremic electroencephalopathy. Clin Neurophysiol 48:583—590, 1980
17. PARKER TF, LAIRD NM, L0wRIE EG: Comparison of the study
groups in the National Cooperative Dialysis Study and a descrip-
tion of morbidity, mortality and patient withdrawal. Kidney mt
(suppl 13) 23:S42—S49, 1983
18. L0wRIE EG, TEEHAN BP: Principles of prescribing dialysis ther-
apy: Implementing recommendations from the National Coopera-
tive Dialysis Study. Kidney mt (suppl 13) 23:Sl13—S122, 1983
19. GOLDSTEIN MB, JINDAL KK: Urea kinetic modelling. Semin Dial
1:82—85, 1988
20. COLLINS A, ILSTRUP K, HANSON G, BERKSETH R, KESHAvIAH P:
Rapid high-efficiency hemodialysis. Artif Organs 10:185—188, 1986
21. COLLINS A, HANSON 0, BERKSETH R, KESHAViAH P: Recirculation
and effective clearances (abstract). Kidney mt 33:219, 1988
22. PEDRINI LA, ZEREIK S, RASMY 5: Causes, kinetics and clinical
implications of post hemodialysis urea rebound. Kidney mt 34:
817—825, 1988
23. LUNDIN AP: Hemodialysis: How much is enough? Semin Dial
1:8—10, 1988
24. KESHAvIAH P, COLLINS A: Hemodialysis: How much is enough?
Semin Dial 1:3—4, 1988
25. LINDSAY RM: Hemodialysis: How much is enough? Semin Dial
1:6—8, 1988
26. GOTCH F, SARGENT J: A mechanistic analysis of the National
Cooperative Dialysis Study (NCDS). Kidney iitt 28:526—534, 1985
27. KESHAVIAH P. COLLINS A: A re-appraisal of the National Cooper-
ative Dialysis Study (abstract). Kidney mt 33:227, 1988
28. LAURENT G, CALEMARD E, CHARRA B: Long dialysis: A review of
fifteen years in one center, 1968—1983. Proc Eur Dial Transplant
Proc 20:122—134, 1983
29. SHAPIRO FL, UMEN A: Risk factors in hemodialysis patient sur-
vival. ASAIO J 6:176—184, 1983
30. End Stage Renal Disease Facility Survey tables. 1987. Contemp
Dial Nephrol 10:35—37, 1989
31. BRUNNER FP, BROYER M, BRYNGER H, CHALLAH S, DYKES SR,
FASSBINDER W, OULES R, RIzzoNi G, SELwOOD NH, WING AJ:
Survival on renal replacement therapy: Data from the EDTA
Registry. Nephrol Dial Transplant 3:109—122, 1988
32. DEGOULET P. LEGRAIN M, REACH I, AIME F, DEVRIE5 C, ROJAS P,
JACOBS C: Mortality risk factors in patients treated by chronic
hemodialysis. Nephron 31:103—110, 1982
33. NEFF MS, EISER AR, SLIFKIN RF, BAUM M, BAEZ A, GUPTA S,
AMARGA E: Patients surviving 10 years of dialysis. Am J Med
74:996—1004, 1983
34. GUTMAN RA: Characteristics of long-term (14 years) survivors of
maintenance dialysis. Nephron 33:111—115, 1983
35. DUMLER F, ZASUWA G, PETERSON E, LEvIN NW: Hemodialysis
survival in a single institution. A risk factor approach (abstract).
Kidney mt 35:245, 1989
36. LEVIN NW, HELD PJ, DIAMOND LH, BOVJERG R, PAULY MV:
Mortality impacts of shorter dialysis procedures (abstract). Kidney
mt 35:254, 1989
37. FENVES AZ, EMME1-F M, WHITE MG, GREENWAY G, MICHAEL5
DB: Carpal tunnel syndrome with cystic bone lesions secondary to
amyloidosis in chronic hemodialysis patients. Am J Kidney Dis
7:130—134, 1986
38. GOREVIC PD, CASEY IT, STONE WJ, DIRAIMONDO CR, PRELLI
FC, FANGIONE B: Beta-2 microglobulin is an amyloidogenic protein
in man. J Cliii invest 76:2425—2429, 1985
39. GEJYO F, YAMADA T, ODANI 5, NAKAGAwA Y, ARAKAWA M,
KUNITOMO T, KATAOKA M, SUZUKI M, HIRASAWA Y, SHIRA-
HAMA T, COHEN AS, SCHMID K: A new form of amyloid protein
associated wtih chronic hemodialysis was identified as /32-micro-
globulin. Biochem Biophys Res Co,nmun 129:701—706, 1985
40. LAURENT G, CALEMARD E, CHARRA B: Dialysis related amyloido-
sis. Kidney mt (suppl 24) 33:32—34, 1988
41. VAN YPERSELE DE STRIHOU C, HONHON B, VANDENBROUCKE JM,
HUAUX JP, NOEL H, MALDAGUE B: Dialysis amyloidosis. Adv
Nephrol 17:401—422, 1988
42. BOUTEILLER 0, TON THAT H, GOUDABLE C: Amyloidosis in
chronic hemodialysis: rheumatologic aspects. Contrib Nephrol
62:67—74, 1988
43. DIRAIMONDO CR, CASEY TT, DIRAIMONDO CV, STONE WJ:
832 Nephrology Forum: Adequacy of dialysis
Pathologic fractures associated with idiopathic amyloidosis of bone
in chronic hemodialysis patients. Nephron 43:22—27, 1986
44. CASEY TT, STONE WJ, DIRAIMONDO CR, BRANTLEY BD, DIRAI-
MONDO CV, GOREVIC PD, PAGE DL: Tumoral amyloidosis of beta
2-microglobulin origin in association with long-term hemodialysis.
Hum Pathol 17:731—738, 1986
45. MAYER G, THUM J, WOLOSZCZUK W, Gi H: Beta-2-micro-
globulin in hemodialysis patients. Effects of different dialyzers and
different dialysis procedures. Am J Nephrol 8:280—284, 1988
46. ZINGRAFF J, BEYNE P, URENA F, UZAN M, MAN NK, DESCHAM
$S-LATSCHA B, DRUEKE T: Influence of haemodialysis membranes
on /32-microglobulin kinetics: in vivo and in vitro studies. Nephrol
Dial Transplant 3:284—290, 1988
47. K.&isi JP, HAGEMANN J, VON HERRATH D, SCHAEFER K: Dif-
ferent handling of beta 2-microglobulin during hemodialysis and
hemofiltration. Nephron 48:132—135, 1988
48. FLOGE J, GRANOLLERAS C, BINGEL M, DESCHODT G, BRANGER B,
OULES R, KOCH KM: /32-microglobulin kinetics during haemodial-
ysis and haemoflltration. Nephrol Dial Transplant 1:223—228, 1987
49. HAKIM RM, FEARON DT, LAZARUS JM: Biocompatibility of dialy-
sis memembranes: Effects of chronic complement activation. Kid-
ney mt 26:194—200, 1984
50. SZTEIN MB, VOGEL SN, SIPE JD, MURPHY PA, MIZEL SB,
OPPENHEIM JJ, ROSENTREICH DL: The role of macrophages in the
acute-phase response SAA inducer is closely related to lymphocyte
activating factor and endogenous pyrogen. Cell Immunol 63:164—
169, 1981
51. BOMMER J, SEELIG P, SEELIG R, GEERLINGS W, BOMMER G, RITZ
E: Determinants of plasma f32 microglobulin concentration: Possi-
ble relation to membrane bicompatibility. Nephrol Dial Transplant
2:22—25, 1987
52. DRUEKE T, ZINGRAFF J: Beta-2 microglobulin-related amyloidosis
in long-term hemodialysis patients: possible pathogenetic mecha-
nisms. Contrib Nephrol 59:99—109, 1987
53. FL0EGE J, GRANOLLERAS C, KOCH KM, SHALDON 5: Which
membrane? Should beta-2-microglobulin decide on the choice of
today's hemodialysis membrane? Nephron 50:177—181, 1988
54. CHANARD J, BIND! P, MAHEUT H, DION JJ, LAVAUD P, BIREM-
BAULT P, LACOUR F, TOUPANCE 0: Low prevalence of carpat
tunnel syndrome in patients hemodialyzed with high-flux mem-
brane (abstract). Nephrol Dial Transplant 3:551, 1988
55. BLUMBERG A, BURG! W: Behavior of /32-microglobulin in patients
with chronic renal failure undergoing hemodialysis, hemodiafiltra-
tion and continuous ambulatory peritoneal dialysis (CAPD). Clin
Nephrol 27:245—249, 1987
56. ROCKEL A, HERTEL J, FIEGEL P, ABDELHAMID S, PANITZ N,
WALE D: Permeability and secondary membrane formation of a
high flux polysulfone hemofilter. Kidney mt 30:429—432, 1986
57. JORSTADT S, SMEBY LC, BALSTAD T, WIDEROE TB: Removal,
generation and adsorption of beta-2 microglobulin during hemofil-
tration with five different membranes, Blood Purf 6:96—105, 1988
58. STONE WJ, HAKIM RM: Beta-2-microglobulin amyloidosis in long
term dialysis patients. Am J Nephrol 9:177—183, 1989
59. LINDSAY RM, SPANNER E: A hypothesis: The protein catabolic
rate is dependent upon the type and amount of treatment in
dialyzed uremic patients. Am J Kidney Dis 13:382—389, 1989
60. TESCHAN PE, GINN HE, BOURNE JR, WARD JW, HAMEL B,
NUNNALLY JC, Musso M, VAUGHN WK: Quantitative indices of
clinical uremia. Kidney Jut 15:676—697, 1979
61. KILEY JE, HINES 0: Electroencephalographic evaluation of ure-
mia. Arch Intern Med 116:67—73, 1975
62. WINEMAN Ri: Rationale of the National Cooperative Dialysis
Study. Kidney mt (suppl 13) 23:58—510, 1983
63. BABB AL, PoPovIcH RP, CHRISTOPHER TG, SCRIBNER BH: The
genesis of the square meter-hour hypothesis. Trans ASAJO 17:
81—91, 1971
64. HAKIM RM, PONTZER MA, TILTON D, LAZARUS JM, GOTTLIEB
MN: Effects of acetate and bicarbonate dialysis in stable chronic
dialysis patients. Kidney mt 28:535—540, 1985
65. RONCO C, BRENDOLAN A, BRAGANTINI L, CHIARAMONTE S,
FABRIS A, FERIANI M, DELL'AQUILA R, MILAN M, SCABARDI M,
PINNA V, LAGREC G: Technical and clinical evaluation of different
short, highly efficient dialysis techniques. Contrib Nephrol 5:61—72,
1987
66. LEVIN SL, VAN EPP5 D: Neutrophil and monocyte alterations in
chronic dialysis patients. Am J Kidney Dis 9:38 1—395, 1987
67. LINDSAY RM, HENDERSON LW: Adequacy of dialysis. Kidney mt
(suppl 24) 33:S92—S99, 1988
68. DIRAIMONDO CR, MCCARLEY P. STONE WJ: Beta-2 microglobulin
in peritoneal dialysis patients: serum levels and peritoneal clear-
ances. Pent Dial Bull 8:43—47, 1988
69. TIELMANS, C, DRATIRA M, BERGMANN P. GOLDMAN M, FLAMION
B, COLLART F, WENS R: Continuous ambulatory peritoneal dialysis
vs haemodialysis: A lesser risk of amyloidosis? Nephrol Dial
Transplant 3:291—294, 1988
70. BENZ RL, SIEGFRIED JW, TESCHAN B: Carpal tunnel syndrome in
dialysis patients: Comparison between continous ambulatory pen-
toneal dialysis and hemodialysis populations. Am J Kidney Dis
11:473—476, 1988
71. MASSEY SG: Parathyroid hormone as a uremic toxin, in Textbook of
Nephrology, edited by MASSRY SG, GLASSOCK RJ, Baltimore,
Williams & Wilkins, 1989, pp 1126—1 144
72. CAMPBELL RA: Other uremic toxins, in Textbook of Nephrology,
edited by MASSEY SO, GLASSOCK RI, Baltimore, Williams &
Wilkins, 1989, pp 1144—1153
73. ESCHBACH JW, EaRlE JC, DOWNING MR, BROWNE JK, ADAMSON
JW: Correction of the anemia of end-stage renal disease with
recombinant human erythropoietin: results of a combined phase I
and II clinical trial. N Engl J Med 316:73—78, 1987
74. BOMMER J, ALEXION C, MULLER-BUHL U, EIFERT J, RITZ E:
Recombinant human erythropoietin therapy in haemodialysis pa-
tients—dose determination and clinical experience. Nephrol Dial
Transplant 2:238—242, 1987
75. KEOWN PA: The effect of recombinant human erythropoietin upon
quality of life and functional capacity of anemic patients or chronic
hemodialysis (abstract). Kidney tnt 35:195, 1989
76. GIBILARO SD, DELANO BG, QUINN R, LUNDIN AP, GALONSICY R,
FREIDMAN EA: Improved quality of life while receiving recombi-
nant erythropoietin (abstract). Kidney Int 35:247, 1989
77. OGDEN DA: Simultaneous reprocessing of hollow-fibre dialyzers
and blood tubing sets for multiple use. Dial Transplant 13:366—375,
1984
78. HAKIM RM, LAZARUS JM: Biochemical parameters in chronic renal
failure. Am J Kidney Dis 11:238—247, 1988
79. SHEMESH 0, GOLBETZ H, Kiuss JP, MYERS BD: Limitations of
creatinine as a filtration marker in glomerulopathic patients. Kidney
Jut 28:830—838, 1985
80. HAMPL H, LOBECK H, BARTEL-SCHWAZE 5, STEIN S, EULITZ M,
LINKE R: Clinical, morphologic, biochemical and immunohisto-
chemical aspects of dialysis associated amyloidosis. Trans ASAJO
33:250—259, 1987
81. DIRAIMONDO CR, STONE WJ: A j32m amyloidosis. mt J Artf
Organs 10:281—283, 1987
